Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
about
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine ProductionRegulation of immunity during visceral Leishmania infectionMononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulationCritical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infectionVCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis.Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.Clinical and experimental advances in treatment of visceral leishmaniasis.Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.Invariant NKT cells drive hepatic cytokinic microenvironment favoring efficient granuloma formation and early control of Leishmania donovani infection.High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.Tissue granuloma structure-function in experimental visceral leishmaniasis.Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c miceIntradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasisLet off the leash: kala-azar following the use of tumour necrosis factor antibodiesBalancing immunity and pathology in visceral leishmaniasis.Leishmania donovani infection induces anemia in hamsters by differentially altering erythropoiesis in bone marrow and spleenImmunobiology of visceral leishmaniasis.Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18Role of tumor necrosis factor alpha in development of immunity against Cryptosporidium parvum infection.Granzyme-mediated regulation of host defense in the liver in experimental Leishmania donovani infection.Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasisA role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.The immunopathology of experimental visceral leishmaniasis.Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cellsProtective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvantModulation of T-cell costimulation as immunotherapy or immunochemotherapy in experimental visceral leishmaniasis.Effects of combined therapy with thalidomide and glucantime on leishmaniasis induced by Leishmania major in BALB/c miceRegulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.Leishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.Gamma Interferon-Regulated Chemokines in Leishmania donovani Infection in the Liver.Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?Functional complexity of the Leishmania granuloma and the potential of in silico modeling.Immune responses during cutaneous and visceral leishmaniasis.Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.Leishmania donovani influenced cytokines and Toll-like receptors expression among Sudanese visceral leishmaniasis patients.
P2860
Q24538777-95D51790-185C-43BE-AF4A-4A10A63AC26FQ27321353-1172AEAA-C538-445B-A6B1-5F951571B27CQ28066034-B918D013-0317-4C6C-A0E7-D9E370303949Q28344860-38F7D62F-9A01-48F8-8620-664B50153BE4Q31036509-48E5F468-C6FE-429E-945F-18B454F76543Q33370533-CCFE4377-6B73-4EA6-B9F6-957EB03E8F0DQ33883498-B2C01722-8E9B-4F70-915B-022D79E6DC0AQ33982648-85CFD493-B374-4969-8FB6-503ED5EFCFBAQ34181985-290B4C91-0E83-4604-8C14-B974C99E91C1Q34211871-31C6DF17-B89E-4F15-9202-7715AE5C2BC6Q34310410-D46AEA78-3918-44DB-9B83-42DD4699032EQ34434760-4871E4BF-2314-4503-B968-1F11679FCE4DQ34510505-52F6518D-E89E-42ED-AB18-D6B602073A7DQ34521577-45BDC249-44A6-4737-99A9-0544C7E6A385Q34533118-3C062B12-71E0-4B80-900A-CCAC58E52B33Q34587432-23E4D1B1-A5C5-417B-9699-93E9DE524016Q34637852-8C02A925-98F6-4E35-81B4-9813EBD598B5Q34641680-BD2D3F17-BDD2-46AA-9277-6B16B782674AQ34648790-09490947-B567-4743-812A-DB7005B1D646Q34721430-6A81239F-7972-4D81-AEE1-69808B45CD2DQ34721449-FA98F2F9-E2E9-4CE4-B90A-4B50874FFE83Q34955529-6485E7FF-FC64-4BFB-9E75-BF7DC9CE33E4Q35103595-F738EE4D-D535-4028-9DE1-8E8A6EE07EF2Q35138682-E939E927-7B1A-4A41-B6CC-32971806C484Q35747613-91885BA1-6D7F-43B3-A920-145AC05B4175Q35809113-46815901-CA91-458E-920F-4EA4EE86E89DQ35884243-08D14BC1-FFB3-4613-BE40-FE3C28AE9A1CQ35893711-671455C7-6DEA-4F1C-B451-733C10C65999Q35947234-5176533E-A54D-43F7-B605-EAE1DACDB791Q36141819-996211A7-4DFC-4851-ABA5-C7C11D7BBF2BQ36376714-CADC838D-8D0A-4BF9-8BE4-812FDA389FBCQ36868265-D24233DA-F18D-4E8C-9E92-F1388E0D2DFAQ36970905-737CFBFE-C054-449D-89A9-3F237203E124Q37388291-BB77ACCB-8DE0-4D2F-B355-72C4E8C72805Q37546954-4CE44B80-465D-4BE7-B053-8A8D031CEAFDQ38040818-AB86B986-3916-4EF3-964A-9627EE72B006Q38083024-7FFA9E56-4A1A-423C-9460-9B2883A339A6Q38235268-106B814B-E685-4CCE-87A0-8E1025162FBDQ38342966-7E9CC42A-48BC-4D31-AABA-46C48F8B63D2Q38873769-AE15A82B-336E-449F-96B2-4E0922E8FBFB
P2860
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@ast
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@en
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@nl
type
label
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@ast
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@en
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@nl
prefLabel
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@ast
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@en
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@nl
P2093
P2860
P1476
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment.
@en
P2093
A Jungbluth
C Montelibano
H W Murray
M W Marino
P2860
P304
P356
10.1128/IAI.68.11.6289-6293.2000
P407
P50
P577
2000-11-01T00:00:00Z